Openbookopenbook
Equity
Harmony Biosciences Holdings(HRMY)
USD --+0.00%
Reward76High
Risk20Low
📊75%Data
Strong 18% profit margin · Revenue growing 21% YoY
HRMY
+0.0 · +0.00%
USD · NASDAQ
Harmony Biosciences Holdings | Healthcare
Quality Compounder
Market Cap:1.62Bn
ℹ️
Reward Rating
76
High
Top 10% (model universe)
75% data coverage
ℹ️
Risk Rating
20
Low
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on HRMY to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: $42.82.

What is Harmony Biosciences Holdings?

, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States.

HRMY · Verdict

Strong reward · low risk

HRMY scores well on valuation and balance sheet with no major weaknesses flagged in the model.

Based on 88% data coverage

HRMY · Verdict

What’s working & what to watch

Strengths 5

  • Valuation100/100

    P/E 8.3× · PEG 0.47

  • Balance sheet99/100

    Interest covered 14.1×

  • Profitability95/100

    18% net margin · 21% ROE

  • Cash flow94/100

    40% free-cash-flow margin

  • Growth75/100

    Rev +25.6% CAGR · earnings -4.4%

No major weaknesses flagged.

Model-based scoring. For information only — not financial advice.

What is Harmony Biosciences Holdings?

, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 1.62B, and a P/E ratio of 8.9x.

Financial Highlights

Investment Breakdown

📈 Growth
Revenue and earnings growing steadily, indicating improving operating performance.
💰 Profitability
Strong margins and consistent earnings support financial stability.
⚠️ Risk
Below-average volatility supports a steadier risk profile.
💸 Valuation
Currently trading below intrinsic value estimates, suggesting upside potential.

OpenBook Logo Analysis

Reward: High (76)

The scoring profile indicates a strong reward potential, driven primarily by valuation and profitability. Risk indicators are low, suggesting a relatively contained downside profile.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap1.62B
P/E Ratio8.8927
Dividend YieldN/A
52 Week High40.87
52 Week Low25.52
Last AnnualDecember
IPO Date8/19/2020
IncorporatedUSA
Shares Outstanding58M
No. of Employees268
IndustryBiotechnology
ExchangeNASDAQ
Beta0.84
CurrencyUSD
Websitewww.harmonybiosciences.com
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.